P. Juréen

发表

Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB

P. Vandamme, F. Portaels, J. Palomino, 2009, Antimicrobial Agents and Chemotherapy.

Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis

P. Juréen, S. Hoffner, S. Ghebremichael, 2003, Antimicrobial Agents and Chemotherapy.

Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.

Biao Xu, M. Joloba, F. Bwanga, 2012, International journal of mycobacteriology.

Detection of First- and Second-Line Drug Resistance in Mycobacterium tuberculosis Clinical Isolates by Pyrosequencing

P. Juréen, S. Hoffner, N. Morcillo, 2012, Journal of Clinical Microbiology.

Rifampin-Isoniazid Oligonucleotide Typing: an Alternative Format for Rapid Detection of Multidrug-Resistant Mycobacterium tuberculosis

J. Palomino, I. Hernández-Neuta, Anandi Martin, 2010, Journal of Clinical Microbiology.

An outbreak investigation of Legionella non-pneumophila Legionnaires’ disease in Sweden, April to August 2018: Gardening and use of commercial bagged soil associated with infections

A. Wallensten, P. Juréen, C. Schönning, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Network Experiences from a Cross-Sector Biosafety Level-3 Laboratory Collaboration: A Swedish Forum for Biopreparedness Diagnostics

M. Forsman, Ö. Melefors, R. Knutsson, 2017, Health security.

Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections

G. Kahlmeter, P. Juréen, S. Hoffner, 2010, Journal of Clinical Microbiology.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

G. Kahlmeter, P. Juréen, S. Hoffner, 2009, The Journal of antimicrobial chemotherapy.

Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis by Pyrosequencing Technology

L. Engstrand, A. Alderborn, P. Juréen, 2006, Journal of Clinical Microbiology.

Intra- and Extracellular Activities of Trimethoprim-Sulfamethoxazole against Susceptible and Multidrug-Resistant Mycobacterium tuberculosis

J. Bruchfeld, P. Juréen, C. Giske, 2014, Antimicrobial Agents and Chemotherapy.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

J. Paues, G. Kahlmeter, J. Bruchfeld, 2016, The Journal of antimicrobial chemotherapy.

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

G. Kahlmeter, P. Juréen, S. Hoffner, 2013, The Journal of antimicrobial chemotherapy.

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

G. Kahlmeter, P. Juréen, S. Hoffner, 2012, Bulletin of the World Health Organization.

Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis.

J. Palomino, Anandi Martin, P. Juréen, 2011, The Journal of antimicrobial chemotherapy.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

G. Kahlmeter, P. Juréen, S. Hoffner, 2010, The Journal of antimicrobial chemotherapy.

Multidrug-resistant Myobacterium tuberculosis caused by the Beijing genotype and a specific T1 genotype clone (SIT No. 266) is widely transmitted in Minsk.

A. Skrahina, P. Juréen, S. Hoffner, 2013, International journal of mycobacteriology.

Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.

G. Kahlmeter, P. Juréen, S. Hoffner, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.

P. Juréen, E. Chryssanthou, T. Schön, 2012, International journal of mycobacteriology.

Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.

P. Juréen, S. Hoffner, J. Werngren, 2011, The Journal of antimicrobial chemotherapy.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

J. Bruchfeld, P. Juréen, C. Giske, 2015, International journal of mycobacteriology.

Meropenem-Clavulanic Acid Has High In Vitro Activity against Multidrug-Resistant Mycobacterium tuberculosis

J. Bruchfeld, P. Juréen, C. Giske, 2015, Antimicrobial Agents and Chemotherapy.

Detection of Drug-Resistant Mycobacterium tuberculosis.

P. Juréen, Anna Engström, 2015, Methods in molecular biology.

Pyrosequencingtuberculosis by Detection of Heteroresistant

P. Juréen, S. Hoffner, Anna Engström, 2014 .

Detection of Heteroresistant Mycobacterium tuberculosis by Pyrosequencing

P. Juréen, S. Hoffner, Anna Engström, 2013, Journal of Clinical Microbiology.

Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.

P. Juréen, S. Hoffner, J. Werngren, 2004, Tuberculosis.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into emergence and spread of multidrug resistance

Thomas Abeel, James E. Galagan, Andrei Gabrielian, 2017, Nature Genetics.

Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis

P. Juréen, S. Hoffner, J. Toro, 2008, Antimicrobial Agents and Chemotherapy.

Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex

J. Parkhill, S. Niemann, T. Walker, 2020, Genome Medicine.

Prioritization of High Consequence Viruses to Improve European Laboratory Preparedness for Cross-Border Health Threats

G. Ippolito, R. Grunow, A. di Caro, 2016, Advances in experimental medicine and biology.

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

Thomas Bo Schön, G. Kahlmeter, P. Juréen, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Reevaluation of the Critical Concentration for Drug Susceptibility Testing of Mycobacterium tuberculosis against Pyrazinamide Using Wild-Type MIC Distributions and pncA Gene Sequencing

Thomas Bo Schön, P. Juréen, S. Hoffner, 2011, Antimicrobial Agents and Chemotherapy.

Mycobacterium tuberculosis against pyrazinamide using wild-type MIC

Thomas Bo Schön, P. Juréen, S. Hoffner, 2011 .

Molecular Characterisation of Antibiotic Resistance in Mycobacterium tuberculosis

P. Juréen, P. Juréen, 2008 .

A luciferase-based assay for rapid assessment of drug activity against Mycobacterium tuberculosis including monitoring of macrophage viability.

P. Juréen, M. Lerm, T. Schön, 2014, Journal of microbiological methods.

Resistance Levels and rpoB Gene Mutations among In Vitro-Selected Rifampin-Resistant Mycobacterium tuberculosis Mutants

P. Juréen, S. Hoffner, E. Huitric, 2006, Antimicrobial Agents and Chemotherapy.